Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02279745 · ClinicalTrials.gov registry record · Phase 2
Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension
A Phase 2 study, sponsored by United Therapeutics.
- Completed
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
NCT02279745 is a Phase 2 study that has completed, run by United Therapeutics. The registered enrollment target is 45 participants.
The verdict
NCT02279745, a Phase 2 study, has completed, sponsored by United Therapeutics.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
Study Summary
This study was an open-label extension study to determine the long-term safety and tolerability of ralinepag in subjects with World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH) who have completed Study APD811-003, or who were assigned to receive placebo and were discontinued due to clinical worsening.
Interventions
- DRUG Ralinepag
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2015-07-08 |
| Est. Completion | 2021-03-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02279745
The ClinicalTrials.gov registry entry for NCT02279745 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is United Therapeutics, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ralinepag is the first listed.
NCT02279745 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02279745 about?
NCT02279745 is a clinical study titled "Long-term Safety and Efficacy of Ralinepag in Pulmonary Arterial Hypertension". This study was an open-label extension study to determine the long-term safety and tolerability of ralinepag in subjects with World Health Organization (WHO) Group 1 pulmonary arterial hypertension (PAH) who have completed Study APD811-003, or who were assigned to receive placebo and were discontinu...
What is the current status of trial NCT02279745?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2015-07-08. Estimated completion is 2021-03-29.
What interventions are being tested in trial NCT02279745?
The interventions under investigation include: Ralinepag (DRUG).
Who is sponsoring clinical trial NCT02279745?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.